NCT05688488 Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
| NCT ID | NCT05688488 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Eye & ENT Hospital of Fudan University |
| Condition | Glottic Web of Larynx |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-05-05 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2023-05-05 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To provide a novel therapy idea and method to solve the clinical problem of postoperative adhesion of bilateral vocal cords, patients enrolled in this study will be applied with curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral vocal cord endoscopically.
Eligibility Criteria
Inclusion Criteria: 1. Patients with bilateral vocal cord diseases who are going to undergo resection of bilateral vocal cord lesions endoscopically. 2. Patients with bilateral vocal cord adhesion who are going to undergo incision of bilateral vocal cord adhesion endoscopically. Exclusion Criteria: 1. Patients with other laryngeal diseases. 2. Patients with cardiac and pulmonary insufficiency. 3. Patients unable to cooperate with the follow-up on time after surgery. 4. Patients who refuse to sign the informed consent after notification. 5. Patients who have a severe allergic disease or allergic history to a variety of drugs. 6. Other circumstances that are not appropriate to be included in the clinical trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05688488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Glottic Web of Larynx. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05688488 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05688488 currently recruiting?
Yes, NCT05688488 is actively recruiting participants. Contact the research team at chenjent@qq.com for enrollment information.
Where is the NCT05688488 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05688488 clinical trial?
NCT05688488 is sponsored by Eye & ENT Hospital of Fudan University. The trial plans to enroll 100 participants.